Diana Crow
Index: 10.1016/j.stem.2017.05.013
Full Text: HTML
How many of the authors who publish in Cell Stem Cell dream that their work will eventually wind up in the clinic? Probably quite a few. In the 10 years since its launch, Cell Stem Cell has featured many innovative discoveries, and several of them have gone on to become the seeds of burgeoning biotechnology companies with therapeutic aspirations. Two scientists who have seen that happen are Benjamin Reubinoff (Figure 1Figure 1) and Derrick Rossi (Figure 2Figure 2), both of whom led the clinical translation of technologies that made their public debut in Cell Stem Cell.
|
ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Supp...
2017-07-13 [10.1016/j.stem.2017.06.004] |
|
Lineage Tracing: Papers and Progress
2017-07-06 [10.1016/j.stem.2017.06.015] |
|
Intestinal Enteroendocrine Lineage Cells Possess Homeostatic...
2017-07-06 [10.1016/j.stem.2017.06.014] |
|
Direct Neuronal Reprogramming: Achievements, Hurdles, and Ne...
2017-07-06 [10.1016/j.stem.2017.06.011] |
|
Making HSCs on Demand: Looking Ahead
2017-07-06 [10.1016/j.stem.2017.06.010] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved